2019冠状病毒病暴发前后视神经炎发病率的变化:2017-2022年全国性研究
该全国性人群回顾性研究纳入2017年1月至2022年12月韩国新诊断视神经炎患者7216例(女性52.7%),比较COVID-19前、非药物干预、疫苗接种和感染四个时期视神经炎的发病风险;结果显示三个疫情时期视神经炎年发病率均较暴发前显著下降,但2021年视神经炎患者中合并多发性硬化、视神经脊髓炎和急性播散性脑脊髓炎的诊断比例较暴发前显著增加。
要点
- 非药物干预期视神经炎年发病率较COVID-19前显著下降(IRR 0.92,95%CI 0.85-1.00,P=0.043)。
- 疫苗接种期和感染期视神经炎年发病率较COVID-19前均显著下降(IRR分别为0.88和0.86)。
- 2021年视神经炎患者中合并多发性硬化、视神经脊髓炎和急性播散性脑脊髓炎的诊断比例较暴发前显著增加(10.93% vs 6.43%,P=0.0002)。
核心结论
- COVID-19非药物干预、疫苗接种和感染时期一般人群中视神经炎发病风险较暴发前未增加。
- COVID-19疫苗接种可能与合并急性播散性脑脊髓炎、多发性硬化、视神经脊髓炎等疾病的视神经炎风险增加相关。
研究设计与样本
- 全国性、基于人群的回顾性研究,查询韩国健康保险审查评估数据库2017年1月至2022年12月新诊断视神经炎数据。
- 共纳入7216例新诊断视神经炎患者,女性占52.7%。
- 数据分为4个时期:COVID-19前(2017-2019年)、非药物干预期(2020年)、全国疫苗接种期(2021年)和全国感染期(2022年)。
主要发现
- 非药物干预期视神经炎年发病率较COVID-19前显著下降(IRR 0.92,95%CI 0.85-1.00,P=0.043),校正年龄和性别。
- 疫苗接种期视神经炎年发病率较COVID-19前显著下降(IRR 0.88,95%CI 0.81-0.95,P=0.001),校正年龄和性别。
- 感染期视神经炎年发病率较COVID-19前显著下降(IRR 0.86,95%CI 0.80-0.93,P<0.001),校正年龄和性别。
- 2021年视神经炎患者中合并多发性硬化、视神经脊髓炎和急性播散性脑脊髓炎的诊断比例较COVID-19前显著增加(10.93% vs 6.43%,P=0.0002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the risk of optic neuritis (ON) during nonpharmaceutical interventions (NPI), vaccination, and infection phases of the coronavirus disease 2019 (COVID-19) pandemic in comparison with levels before the outbreak in pediatric and adult populations in South Korea. DESIGN: A nationwide, population-based retrospective study. PARTICIPANTS: South Korean individuals with a primary diagnosis of ON received between January 2017 and December 2022. METHODS: The Korean Health Insurance Review and Assessment database was queried for new diagnoses of ON between January 2017 and December 2022. Data were divided into 4 periods: before COVID-19 (2017-2019), NPI (2020), nationwide vaccination (2021), and nationwide infection (2022). The risk of ON development for each period was calculated and compared with levels before COVID-19, with 95% confidence intervals (CIs) reported. MAIN OUTCOME MEASURES: Incidence rate ratio (IRR) of ON for each period. RESULTS: A total of 7216 patients (52.7% female patients) were included in the study, with patients receiving a diagnosis of ON as follows: 3770 patients before COVID-19 (2017-2019), 1193 patients during NPI, 1135 patients during vaccination, and 1118 patients during the infection phases. The annual incidence of ON during NPI (IRR, 0.92; 95% CI, 0.85-1.00; P = 0.043), vaccination (IRR, 0.88; 95% CI, 0.81-0.95; P = 0.001), and infection (IRR, 0.86; 95% CI, 0.80-0.93; P < 0.001) phases significantly decreased compared with levels before COVID-19 when adjusted for age and sex. The proportions of diagnosis with multiple sclerosis (MS), neuromyelitis optica (NMO), and acute disseminated encephalomyelitis (ADEM) among patients in whom ON developed increased significantly in 2021 in comparison with levels before COVID-19 (10.93% vs. 6.43%; P = 0.0002). CONCLUSIONS: The risks of ON development during the NPI, vaccination, and infection phases of COVID-19 did not increase in comparison with levels before the outbreak in the general population. However, COVID-19 vaccination may be associated with increased risks of ON associated with diseases such as ADEM, MS, and NMO. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Lee JS, Lee SW, Lee NK, et al. Changes in the Incidence of Optic Neuritis before and after the Coronavirus Disease 2019 Outbreak: A Nationwide Study 2017-2022. Ophthalmology. 2024. PMID: 39278270. doi:10.1016/j.ophtha.2024.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。